Dialpad Introduces TruCaaS to Business Communications With Launch of Dialpad Meetings for Single, Unified View
13.7.2021 13:10:00 EEST | Business Wire | Press release
Dialpad Inc., the industry leader in AI-powered communication and collaboration, today announced a truly unified approach to communications as a service. With the launch of Dialpad Meetings, the company is bringing its suite of products closer together across both business communications and customer engagement all on one unified, aesthetically cohesive platform with AI at its core.
Dialpad Meetings, formerly known as UberConference, adds new capabilities and establishes the Dialpad cloud communications platform as the one place for a truly unified Communications as a Service (TruCaaS) experience. With a TruCaaS solution delivered through a single pane of glass with an intuitive interface, Dialpad helps customers simplify business collaboration and avoid the growing phenomenon of “app overload.”
“At Dialpad, we believe when the right people come together anything is possible, and we want our brand to reflect this spirit of connection, collaboration and productivity in this new work-from-anywhere world,” said Craig Walker, CEO of Dialpad. “With today’s announcements, we are resetting expectations for communication experiences by building a business communication platform that is more beautiful, accessible, easy to deploy and easy to use — to help businesses of any size start, grow and scale.”
To bring the vision of TruCaaS to life, Dialpad is making the following capabilities available in its single, powerful platform:
-
Dialpad Meetings - The reliable UberConference technology customers know and love with a new look and set of features, including:
- Video conferencing in HD quality for an in-the-room experience
- Real-time Voice Intelligence (Vi™) provides live note-taking and automated transcription analysis, enabling attendees to focus on the conversation and ensure key moments are not missed.
- Start and join Dialpad Meetings from any direct message, group message or channel within the Dialpad app. With Dialpad Meetings natively built into the platform, users are not required to manage multiple tabs or windows.
- Emoji reactions and expressions build social connections with team members and provide feedback in real-time without interruptions.
- Dialpad Channels - With one click, Dialpad Channels offers teams a “light lift” collaboration tool for quick text and/or audio conversations. By providing a space for informal chats, office hours and other water cooler conversations, Dialpad Channels combats video conferencing fatigue and reduces the need for formal 30-minute meetings.
- Mobile screen sharing - Dialpad users can now share their screens on phone calls, whether everyone is a Dialpad user or not. No need to set an official meeting or jump onto a conference call to quickly resolve issues, collaborate on projects or do virtual walkthroughs.
- Global availability - Dialpad Meetings is available through the Dialpad platform with connectivity in 49 countries.
After winning TechCrunch Disrupt NYC in 2012 for UberConference and igniting the work-from-anywhere movement, Dialpad is disrupting an industry built on legacy thinking. As part of this vision and aligned with its TruCaaS approach, Dialpad is launching its Work Beautifully campaign to further support and enable the hybrid workplace.
“Work Beautifully is the big-picture concept that the Dialpad brand and products aspire to. Not only do our talk, messaging, meetings and contact center products work beautifully, they enable others to work beautifully and collaboratively together,” said Morgan Norman, Chief Marketing Officer, Dialpad. “This bold, new visual identity honors Dialpad’s ground-breaking story, its history of innovation in communications, and is deeply rooted in the company’s core values: do the right thing, every voice matters, and experience first.”
The future of work is not restrained by employee or customer location, but is instead borderless; enabled by AI across every experience and seamlessly integrated into how people collaborate and create. Companies that embrace work-from-anywhere technology and empower employee and customer experiences with AI have a significant advantage over those that hold tight to outdated modes of communication, collaboration and productivity. Dialpad’s new release with integrated talk, messaging, meetings and contact center — all powered by AI across every experience — arrives at the right moment to help businesses thrive in this post-pandemic, work-from-anywhere world.
“Work Beautifully means simplicity and ease. Dialpad even takes notes and transcribes calls for us. It’s that flow state where work doesn’t feel like work anymore,” said Chad Pierce, Head of Building Technology, WeWork. “Dialpad makes it easy for our teams to stay close, wherever work finds them and frees our teams to collaborate from anywhere on the planet.”
Additional Resources
- Get started with Dialpad today on a 14-day free trial
- Learn more about Dialpad Channels
- Explore the what, how and why of Voice Intelligence in the contact center
- Discover how Dialpad utilizes AI to unify UCaaS and CCaaS
Social Networks:
- Web: https://www.dialpad.com/
- Blog: https://www.dialpad.com/blog/
- Twitter: https://twitter.com/dialpadHQ/
- LinkedIn: https://www.linkedin.com/company/dialpad/
- Facebook: https://www.facebook.com/Dialpadhq/
- Instagram: https://www.instagram.com/Dialpad/
About Dialpad
Dialpad is the leading cloud communications platform for talk, messaging, meetings and contact center in one beautiful app. Dialpad’s platform delivers AI across every employee and customer experience through real-time transcriptions, live agent coaching and sentiment analysis. More than 73,000 of the world’s most innovative businesses, including Domo, Motorola Solutions, Netflix, Splunk, Stripe, T-Mobile, Twitter, Uber and WeWork use Dialpad to connect and collaborate. Dialpad is backed by the world’s leading investors including Amasia, Andreessen Horowitz, Felicis Ventures, GV, ICONIQ Capital, OMERS Growth Equity, Salesforce Ventures, Scale Ventures, Section 32, SoftBank Corp., T-Mobile Ventures and Work-Bench. Visit www.dialpad.com for more information and to request a demo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005389/en/
Contact information
Gavin Gustafson
gavin@dialpad.com
801-255-9915
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
